Prof Andrew Abell and team at Calpain Therepeutics win $100,000 Business Prize

Prof Andrew Abell of IPAS and the team at Calpain Therapeutics who are commercialising a drug which has the potential to delay cataracts from forming, and slow their growth, have been named the 2011 winners of The University of Queensland (UQ) Business School’s $100,000 ENTERPRIZE competition.

Calpain Therapeutics co-founders Dr Tim Lovell and Prof Andrew Abell, with team member Dr Victoria Kopetz, accepted the winner’s cheque last night after a final business pitch to the Enterprize judges at Pitch Day, held at the Brisbane Powerhouse.

Dr Lovell said the Calpain Therapeutics team was “thrilled to have won such a prestigious competition as Enterprize” – especially on what was World Sight Day (a global initiative to raise public awareness of blindness and vision impairment as major public health issues).

Calpain Therapeutics acknowledge key contributions from a large team in New
Zealand where Prof Abell worked prior to moving to Adelaide, The University of Canterbury (Jim Coxon), Lincoln University (James Morton and Roy Bickerstaffe) and Douglas Pharmaceuticals.

Many congratulations to Prof Andrew Abell and team on this excellent result.

Read the full article in the News Maker.


Posted on October 14, 2011, in CommercialNews, IPASnews, ResearchNews. Bookmark the permalink. Leave a comment.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: